{"id":8419,"date":"2012-07-10T22:10:56","date_gmt":"2012-07-10T22:10:56","guid":{"rendered":"http:\/\/www.ilmelanoma.com\/melanoma\/melanomas-medical-therapy\/braf-v600e\/"},"modified":"2026-10-17T11:22:54","modified_gmt":"2026-10-17T10:22:54","slug":"braf-v600e","status":"publish","type":"page","link":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/","title":{"rendered":"BRAF V600E in melanoma"},"content":{"rendered":"<div class=\"im26-diagnosis-guide\">\n<aside class=\"im26-dg-related\"><strong>How to read this guide<\/strong><\/p>\n<p>Educational information based on the cited sources, not an individual prescription. Editorial revision is not equivalent to specialist clinical validation. Decisions and treatments must be agreed with the treating team; benefits, risks and availability depend on the case.<\/p>\n<\/aside>\n<nav class=\"im26-dg-toc\" aria-label=\"On this page\"><strong>On this page<\/strong><\/p>\n<ol>\n<li><a href=\"#med-biologia\">A cellular signal, not a diagnosis<\/a><\/li>\n<li><a href=\"#med-test\">Tumour testing and its limitations<\/a><\/li>\n<li><a href=\"#med-terapie\">When the result changes treatment options<\/a><\/li>\n<li><a href=\"#med-ereditarieta\">Somatic mutation, family history and research<\/a><\/li>\n<\/ol>\n<\/nav>\n<section class=\"im26-dg-section\" id=\"med-biologia\">\n<h2>A cellular signal, not a diagnosis<\/h2>\n<p>BRAF is a gene encoding a protein kinase involved in the MAPK signalling pathway. This signalling chain helps regulate cell growth and proliferation. Certain BRAF alterations can keep the signal active when it should not be and can become a drug target.<\/p>\n<p>V600E describes replacement of valine by glutamic acid at position 600 of the protein. In current nomenclature, on reference transcript NM_004333.6, it corresponds to c.1799T&gt;A, p.Val600Glu. Older documents may use previous numbering: interpreting a report requires the gene, variant and reference sequence used.<\/p>\n<div class=\"im26-dg-gallery\">\n<figure><a href=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/12\/melanoma-therapy.jpg\"><img loading=\"lazy\" src=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/12\/melanoma-therapy.jpg\" width=\"800\" height=\"300\" loading=\"lazy\" decoding=\"async\" alt=\"Illustrative molecular model retained from the site archive.\"\/><\/a><figcaption>Illustrative molecular model retained from the site archive.<\/figcaption><\/figure>\n<\/div>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/13961\/\">NCBI ClinVar \u2014 BRAF c.1799T&gt;A, p.Val600Glu<\/a>; <a href=\"https:\/\/www.cancer.gov\/types\/skin\/hp\/melanoma-treatment-pdq\">National Cancer Institute \u2014 Melanoma Treatment (PDQ), health professional version<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-test\">\n<h2>Tumour testing and its limitations<\/h2>\n<p>BRAF testing is performed when it can guide treatment, using validated methods and adequate material. A single commercial brand should not be described as the only possible test. The laboratory and <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/istopatologia-del-melanoma\/\">pathologist<\/a> assess specimen quality, tumour-cell content and the method\u2019s ability to detect relevant variants.<\/p>\n<p>V600E is not the only BRAF variant: V600K and non-V600 alterations also exist and must not automatically be treated as equivalent. A negative result also depends on what the assay tests for and specimen quality. With incomplete or discordant results, the specialist may consider further testing; the report is not interpreted in isolation.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tafinlar\">EMA \u2014 Tafinlar: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-terapie\">\n<h2>When the result changes treatment options<\/h2>\n<p>BRAF V600 positivity may make combinations blocking BRAF and MEK available, including <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/dabrafenib-and-trametinib\/\">dabrafenib with trametinib<\/a> and <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\">vemurafenib<\/a> with <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/\">cobimetinib<\/a>. Evidence for one pair does not justify constructing different combinations. Indication, stage, previous treatment and individual circumstances remain decisive.<\/p>\n<p>Immunotherapy can also be used in BRAF-mutated melanoma. Choice and sequence cannot be inferred from the test alone: progression rate, symptoms, disease sites, overall health and contraindications matter. DREAMseq informs discussion of sequences in the population studied without establishing an unvarying rule for every patient.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9839305\/\">DREAMseq \u2014 Randomized treatment-sequence trial (2022\/2023)<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mekinist\">EMA \u2014 Mekinist: indications, product information and leaflet<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-ereditarieta\">\n<h2>Somatic mutation, family history and research<\/h2>\n<p>A mutation found in a tumour does not automatically show that it is inherited or present throughout the body. Assessment of familial predisposition is a separate pathway based on personal and family history and, when indicated, genetic counselling. BRAF V600E alone is not a screening test for relatives.<\/p>\n<p>Likewise, a molecular target does not replace histological examination and <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/\">staging<\/a>. Studies of new combinations, resistance or less common variants must be distinguished from established indications. Ask for the report and treatment proposal to be explained together: \u201cwhich variant was found, which option does it make possible and what alternatives remain?\u201d.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a>; <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/13961\/\">NCBI ClinVar \u2014 BRAF c.1799T&gt;A, p.Val600Glu<\/a>; <a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a>.<\/small><\/p>\n<\/section>\n<aside class=\"im26-dg-related\">\n<h2>Continue reading<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/\">Medical treatment of melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/drugs-approved-for-melanoma\/\">Approved medicines for melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/\">Ipilimumab in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\">Vemurafenib in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/\">Cobimetinib in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/dabrafenib-and-trametinib\/\">Dabrafenib and trametinib in melanoma<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/#med-sperimentali\">Experimental treatments: evidence, limitations and trial access<\/a><\/p>\n<\/aside>\n<section class=\"im26-dg-sources\">\n<h2>Sources and update<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/13961\/\">NCBI ClinVar \u2014 BRAF c.1799T&gt;A, p.Val600Glu<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/types\/skin\/hp\/melanoma-treatment-pdq\">National Cancer Institute \u2014 Melanoma Treatment (PDQ), health professional version<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tafinlar\">EMA \u2014 Tafinlar: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9839305\/\">DREAMseq \u2014 Randomized treatment-sequence trial (2022\/2023)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mekinist\">EMA \u2014 Mekinist: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a><\/li>\n<\/ul>\n<p>Editorial revision and source consultation: 17 October 2026. Study dates distinguish current evidence from historical documents. This date does not certify specialist clinical review.<\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>What the mutation means, how it is tested and why it can guide treatment without independently defining diagnosis or prognosis.<\/p>\n","protected":false},"author":13,"featured_media":0,"parent":5586,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-8419","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BRAF V600E - melanoma<\/title>\n<meta name=\"description\" content=\"The BRAF gene is a key element in cellular signaling pathways involved in the growth and survival of cancer cells.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BRAF V600E - melanoma\" \/>\n<meta property=\"og:description\" content=\"The BRAF gene is a key element in cellular signaling pathways involved in the growth and survival of cancer cells.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/\" \/>\n<meta property=\"og:site_name\" content=\"Il Melanoma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-17T10:22:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/12\/melanoma-therapy.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/\",\"name\":\"BRAF V600E - melanoma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/12\\\/melanoma-therapy.jpg\",\"datePublished\":\"2012-07-10T22:10:56+00:00\",\"dateModified\":\"2026-10-17T10:22:54+00:00\",\"description\":\"The BRAF gene is a key element in cellular signaling pathways involved in the growth and survival of cancer cells.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/12\\\/melanoma-therapy.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/12\\\/melanoma-therapy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/braf-v600e\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medical treatment of melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"BRAF V600E\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"name\":\"Il Melanoma\",\"description\":\"la guida alla conoscenza, prevenzione e cura del melanoma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\",\"name\":\"Il Melanoma\",\"alternateName\":\"ilmelanoma.com\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"width\":300,\"height\":29,\"caption\":\"Il Melanoma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BRAF V600E - melanoma","description":"The BRAF gene is a key element in cellular signaling pathways involved in the growth and survival of cancer cells.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/","og_locale":"en_US","og_type":"article","og_title":"BRAF V600E - melanoma","og_description":"The BRAF gene is a key element in cellular signaling pathways involved in the growth and survival of cancer cells.","og_url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/","og_site_name":"Il Melanoma","article_modified_time":"2026-10-17T10:22:54+00:00","og_image":[{"url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/12\/melanoma-therapy.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/","url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/","name":"BRAF V600E - melanoma","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/#primaryimage"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/12\/melanoma-therapy.jpg","datePublished":"2012-07-10T22:10:56+00:00","dateModified":"2026-10-17T10:22:54+00:00","description":"The BRAF gene is a key element in cellular signaling pathways involved in the growth and survival of cancer cells.","breadcrumb":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/#primaryimage","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/12\/melanoma-therapy.jpg","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/12\/melanoma-therapy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/"},{"@type":"ListItem","position":2,"name":"Medical treatment of melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/"},{"@type":"ListItem","position":3,"name":"BRAF V600E"}]},{"@type":"WebSite","@id":"https:\/\/www.ilmelanoma.com\/en\/#website","url":"https:\/\/www.ilmelanoma.com\/en\/","name":"Il Melanoma","description":"la guida alla conoscenza, prevenzione e cura del melanoma","publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ilmelanoma.com\/en\/#organization","name":"Il Melanoma","alternateName":"ilmelanoma.com","url":"https:\/\/www.ilmelanoma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","width":300,"height":29,"caption":"Il Melanoma"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/8419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=8419"}],"version-history":[{"count":4,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/8419\/revisions"}],"predecessor-version":[{"id":11115,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/8419\/revisions\/11115"}],"up":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/5586"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=8419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}